List of Emend drug patents

Emend is owned by Merck.

Emend contains Aprepitant.

Emend has a total of 1 drug patent out of which 0 drug patents have expired.

Emend was authorised for market use on 26 March, 2003.

Emend is available in capsule;oral dosage forms.

Emend can be used as prevention of postoperative nausea and vomiting; for the prevention of nausea and vomiting associated with chemotherapy.

The generics of Emend are possible to be released after 26 September, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132 MERCK Pharmaceutical composition of a tachykinin receptor antagonist
Sep, 2027

(4 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 26 March, 2003

Treatment: Prevention of postoperative nausea and vomiting; For the prevention of nausea and vomiting associated with chemotherapy

Dosage: CAPSULE;ORAL

How can I launch a generic of EMEND before it's patent expiration?
More Information on Dosage

Emend is owned by Msd Merck Co.

Emend contains Aprepitant.

Emend has a total of 1 drug patent out of which 0 drug patents have expired.

Emend was authorised for market use on 17 December, 2015.

Emend is available in for suspension;oral dosage forms.

Emend can be used as prevention of nausea and vomiting associated with chemotherapy (cinv).

The generics of Emend are possible to be released after 26 September, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132 MSD MERCK CO Pharmaceutical composition of a tachykinin receptor antagonist
Sep, 2027

(4 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 17 December, 2015

Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of EMEND before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in